read the small print of the 1572 the essential gcp document
TRANSCRIPT
![Page 1: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/1.jpg)
Read the SMALL PRINT of the 1572
The Essential GCP Document
![Page 2: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/2.jpg)
Good Clinical Practice (GCP)
A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that
the Data and Reported Results are Credible, and Accurate,
and that the Rights, Integrity, and Confidentiality of Trial
Subjects are Protected.
= Quality Data
= Ethics
Quality Data + Ethics = GCP
![Page 3: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/3.jpg)
Obligations of Investigators Video
A “GCP Day” in the life of a clinical researcher
![Page 4: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/4.jpg)
GCPs: Discussion
What “ethics” process was shown in the video?– the Rights, Integrity, and Confidentiality of Trial
Subjects are Protected.
What “data quality” concepts were shown?– the Data and Reported Results are Credible, and
Accurate
![Page 5: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/5.jpg)
Form FDA 1572: It’s the Law!
21 Code of Federal Regulations 312.53 (c) (1)– Before permitting an investigator to begin
participation in an investigation, the sponsor shall obtain the following:1) A signed investigator statement (Form FDA-1572)
![Page 6: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/6.jpg)
Form FDA 1572: Location
DHHS’s Program Support Center (PSC): http://forms.psc.gov/ – Click on “FDA” for current version of 1572 (and
instructions)
Note: In last year there have been 3 versions– Sep 30, 2002– Nov 30, 2002– Jan 31, 2006
![Page 7: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/7.jpg)
Investigator Information
Education, Training, and Experience
Study Location
Laboratory Information
IRB Information
List of Subinvestigators
Expiry Date
![Page 8: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/8.jpg)
Bioresearch Monitoring Information System File (BMIS)
http://www.fda.gov/oc/gcp/clinenforce.html Abstracts IND study information from 1572 and
other documents Contains information on:
– Investigators – Contract Research Organizations (CROs)– Institutional Review Boards (IRBs)
Lists separate information entry each time a new IND is submitted
![Page 9: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/9.jpg)
Expiry Date
Investigator Information
Education, Training, and Experience
Study Location
Laboratory Information
IRB Information
List of Subinvestigators
Protocol/IND Number (Sponsor Information)
![Page 10: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/10.jpg)
IND Requirement
Investigational New Drug [21CFR312.3]– New drug, or – New biological drug – New biological product used in vitro for diagnostic
purposes
Phase 1, 2, or 3 studies– Administered or dispensed to, or used in, one or
more human subjects
![Page 11: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/11.jpg)
Clinical Phase
Filing Instructions
Investigator Signatureand Date
Commitments• S• M• A• L• L
• P• R• I• N•T
![Page 12: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/12.jpg)
1572 Commitments: Box 9
S _______ M ______ ______ A _____ to _______ L ____ __________ ________ L et FDA Inspect
__P__ _______ _______ R etain Records I _____ _______ N ____ _ _ _ T ____ ______
![Page 13: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/13.jpg)
1572 Commitments: Box 9
S _______ M ______ ______ A _____ to _______ L ____ __________ ________ L et FDA Inspect
__P__ _______ _______ R etain Records I _____ _______ N ____ _ _ _ T ____ ______
upervise
aintain Recordsdhere Protocolearn Investigator’s Brochure
Re ort Adverse Events
nform Subjects
otify I R Brain Staff
![Page 14: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/14.jpg)
1572 Commitments: Box 9
S _______ M ______ ______ A _____ to _______ L ____ __________ ________ L et FDA Inspect
__P__ _______ _______ R etain Records I _____ _______ N ____ _ _ _ T ____ ______
upervise
aintain Recordsdhere Protocolearn Investigator’s Brochure
Re ort Adverse Events
nform Subjects
otify I R Brain Staff
Data Quality
Ethics
PeopleNeeds
![Page 15: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/15.jpg)
1572: Discussion Points
For what studies is the 1572 used?
Who can be the investigator (i.e. signatory)?
Who can be a sub investigator (Box 6)?
![Page 16: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/16.jpg)
1572 Problem Cases
![Page 17: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/17.jpg)
FDA Warning Letters (WL)
A post FDA inspection document An informal advisory to a firm communicating
FDA's position on a matter but does not commit FDA to taking enforcement action
http://www.fda.gov/oc/gcp/clinenforce.html
![Page 18: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/18.jpg)
WL (5 Jun 02): Hassman, MD
The investigator agreement you signed requires you to personally conduct or supervise the clinical investigation (see FDA Form 1572). – FDA’s investigation revealed that you failed to
adequately supervise those aspects of clinical investigations which you did not personally conduct. As described in more detail …, this lack of supervision resulted in submission of false information to the sponsor and failure to maintain adequate and accurate case histories.
![Page 19: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/19.jpg)
WL(17 Apr 02): Yu, MD, PhD
“You failed to obtain a signed investigator statement, Form FDA 1572– from all investigators prior to permitting them to
begin participation in the investigation.”
“You failed to provide a complete list of the sub-investigators – who assisted you in the conduct of the
investigation.”
![Page 20: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/20.jpg)
FDA Problem Investigators Lists
Restricted List– Names of all clinical investigators who have agreed
to certain restrictions with respect to their conduct of clinical investigations
http://www.fda.gov/ora/compliance_ref/bimo/restlist.htm
![Page 21: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/21.jpg)
Restrictions List: Cases
David P. Faxon, MD, Los Angeles, CA
CDER R 19-Jun-2002
By consent agreement. For 3 years: Shall not be principal investigator for more than two (2) FDA regulated clinical investigations at any one time (with additional provisions); shall not be principal clinical investigator for study that enrolls more than 25 subjects at the site where he is the principal investigator; and additional provisions.
Lois Anne Katz, MD, New York, NY
CDER R 23-Aug-2002
For 3 years: Shall not be principal investigator for more than one additional study clinical investigation at any one time; attend at least educational programs on clinical research studies; arrange training and education of staff in conduct of clinical trials; provide annual certification of compliance
![Page 22: Read the SMALL PRINT of the 1572 The Essential GCP Document](https://reader035.vdocuments.site/reader035/viewer/2022062518/56649ecf5503460f94bdd847/html5/thumbnails/22.jpg)
“The obligations of the 1572 must be applied to all clinical
research."Anonymous
15 2